Antibody Drug Conjugate News and Research

RSS
Waters debuts industry-first extended-range MALS detector for UHPLC/UPLC, powering rapid characterization of large molecules

Waters debuts industry-first extended-range MALS detector for UHPLC/UPLC, powering rapid characterization of large molecules

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

Precision medicine tools offer hope for patients with rare blood cancers

Precision medicine tools offer hope for patients with rare blood cancers

VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer

VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

One‑Step ADC Manufacturing Reaches 95% Yield in Under One Hour, BioDlink White Paper Reveals

One‑Step ADC Manufacturing Reaches 95% Yield in Under One Hour, BioDlink White Paper Reveals

Precision immunotherapy for TRBC2-positive T-cell malignancies

Precision immunotherapy for TRBC2-positive T-cell malignancies

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

VALANX Biotech establishes Board of Directors

VALANX Biotech establishes Board of Directors

Novel therapy reduces tumor growth in models of triple-negative breast cancer

Novel therapy reduces tumor growth in models of triple-negative breast cancer

Lymphoma resistance mechanisms and future therapies

Lymphoma resistance mechanisms and future therapies

TROP2 identified as a promising therapeutic target for renal medullary carcinoma

TROP2 identified as a promising therapeutic target for renal medullary carcinoma

AI indelibly transforms solid tumor drug development

AI indelibly transforms solid tumor drug development

New drug can have a promising effect in cancer patients with active brain metastases

New drug can have a promising effect in cancer patients with active brain metastases

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

Repurposed diabetes drugs boost CAR T therapy effectiveness in bladder cancer

Repurposed diabetes drugs boost CAR T therapy effectiveness in bladder cancer

BioDlink Commends Junshi Biosciences as its Bispecific ADC Candidate JS212 Receives IND Approval

BioDlink Commends Junshi Biosciences as its Bispecific ADC Candidate JS212 Receives IND Approval

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

Teclistamab shows promising results in heavily pretreated multiple myeloma

Teclistamab shows promising results in heavily pretreated multiple myeloma

First-in-class antibody-drug conjugate shows high response rates in rare blood cancer trial

First-in-class antibody-drug conjugate shows high response rates in rare blood cancer trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.